Approach & Progress
NodThera is unlocking the significant therapeutic potential of NLRP3 inflammasome activation inhibitors through our novel drug discovery platform.
Building on our knowledge of the medicinal chemistry, biological activity and mechanism of action of NLRP3 inflammasome inhibitors, we are creating a next-generation pipeline of small molecules that are optimized for potency, PK and tissue penetration. We are also focusing on structural attributes that enable individual candidate molecules to be targeted to specific disease indications.
We have advanced our lead development candidate, NT-0167, into a Phase 1 clinical trial. This first-in-human clinical study is evaluating the candidate for safety and tolerability as well as pharmacokinetic and pharmacodynamic response. We are also advancing our pipeline of other small molecule NLRP3 inhibitors — including compounds that cross the blood-brain barrier — and further progressing our drug discovery efforts.
We plan to target a range of diseases where NLRP3 overactivation has been implicated, from fibrosis (including NASH and idiopathic pulmonary fibrosis) to neurodegenerative diseases.
Inflammatory bowel disease